Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Inflammation may be key in rare muscle disease

NCT ID NCT04694456

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This pilot study examined whether inflammation, measured by cytokines in the blood, plays a role in type 1 facioscapulohumeral muscular dystrophy (FSHD1). Researchers compared 20 FSHD1 patients with healthy controls to see if certain inflammatory markers are higher in the disease. Participants also underwent walking tests, muscle strength tests, and whole-body MRI scans to link inflammation with muscle damage. The goal is to understand the disease better and potentially identify new treatment targets.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could point toward inflammation as a target for future FSHD1 treatments.
What could go wrong
This is a small, early pilot study with only 20 patients. It measures biomarkers, not treatment effects, so results may not lead directly to therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Jan 2018

Finished

May 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * male or female age 18 to 75 * suffering from genetically confirmed FSHD1 (\<11 D4Z4 repeat units on permissive chromosome 4 allele) * ambulant or walking with assistance * Manual Muscle Testing ≥4 for 1 of lower limb muscles Exclusion Criteria: * pregnancy or breast feeding * stay in tropical/subtropical country within 3 months * physical exercice within 10 hours * specific diet (e.g. hypocaloric or cholesterol lowering diet) * regular alcohol consumption; drug consumption within 3 months * immunosuppressive or immonumodulating drug within 2 weeks or for more than 3 months withing last 6 months * vaccination, blood transfusion of immunoglobulin treatment within 3 months * infection within 3 weeks; HIV, HBV, HCV seropositivity * chronic inflammatory and/or autoimmune or allergic disease from the gut (Crohn disease, ulcerative colitis), skin (psoriasis, atopic dermatitis), joints (rhumatoid arthritis), nervous system (multiple sclerosis), diabetes type I and II * neurodegenerative disorders (Alzheimer's or Parkinson's diseases) * diagnosed cancer not under remission for at least 5 years * participation in the last 3 months in a research clinical trial with exposure to a pharmaceutical product or a medical device * muscular MRI contraindication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Facioscapulohumeral muscular dystrophy type 1 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

facioscapulohumeral muscular dystrophy 1 muscular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Muscular dystrophies

Contacts and locations

Locations

  • CHU de NICE

    Nice, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.